SEC filings and other documents

Q2 revenue rose 10% YoY with strong cash flow, debt reduction, and FY2027 guidance maintained.

Q1 revenue up 13% year-over-year, net income positive, and fiscal 2027 guidance reaffirmed.

All proposals, including director elections and auditor ratification, were approved by stockholders.

FY27 revenue guidance cut on pharma headwinds, but margin and cash flow outlooks remain robust.

Q3 saw double-digit growth, record margins, and new growth levers from AccessOne and HCP marketing.

Achieved first positive net income, 15% revenue growth, and announced $160M AccessOne acquisition.

Strong revenue and EBITDA growth, raised guidance, and new share repurchase plan announced.

Q4 revenue up 15% YoY, strong cash flow, and fiscal 2026 guidance reaffirmed.

Revenue up 17% and net loss halved, with positive adjusted EBITDA and improved cash flow.